66535-86-2

Usage

Uses

Used in Pharmaceutical Industry:
Lotrifen is used as a lead compound in the topological virtual screening process for discovering new anticonvulsant drugs from chemical diversity. Its unique structure and potential to modulate specific biological targets make it a valuable asset in the search for novel therapeutic agents to treat epilepsy and other seizure disorders.
In the pharmaceutical industry, lotrifen serves as a starting point for further research and development, with the aim of optimizing its anticonvulsant properties and evaluating its safety and efficacy in preclinical and clinical studies. By leveraging the power of topological virtual screening, researchers can identify and explore a wide range of chemically diverse compounds, such as lotrifen, to accelerate the discovery of new and effective treatments for various neurological conditions.

InChI:InChI=1/C16H10ClN3/c17-13-7-5-12(6-8-13)15-18-16-14-4-2-1-3-11(14)9-10-20(16)19-15/h1-10H

Upstream product

• 132401-91-3 3-(4-chlorophenyl)-1,4,2-dioxazol-5-one 
• 119-65-3 isoquinoline 
• 122-01-0 4-chloro-benzoyl chloride 
• 1613-88-3 4-chloro-N-hydroxybenzamide 

Relevant academic research and scientific papers

Cu(II)-Catalyzed C-H Amidation/Cyclization of Azomethine Imines with Dioxazolones via Acyl Nitrenes: A Direct Access to Diverse 1,2,4-Triazole Derivatives

We report a Cu(II)-catalyzed C-H amidation/cyclization of azomethine imines with dioxazolones as acyl nitrene transfer reagents under additive-and ligand-free conditions. An array of 1,2,4-triazolo[1,5-a]pyridine derivatives were afforded in moderate to good yields with excellent functional group tolerance. In addition, scale-up reaction and photoluminescence properties were discussed.

2-Substituted phenyl-s-triazolo[5,1-a] isoquinoline compounds

A new process for preparing s-triazolo[5,1-a]-isoquinoline derivatives of the formula STR1 wherein A represents the group --CH2 --CH2 -- or --CH=CH--; R is selected from hydrogen, amino, lower alkylamino, di-lower alkylamino, acylamino, diacylamino, ureido, thioureido, carbethoxythioureido, benzoylthioureido, sulfhydryl, lower alkyl, trifluoromethyl, phenyl, substituted phenyl, pyridyl, methylpyridyl and dimethylpyridyl; and R1 and R2 each independently represents hydrogen or lower alkoxy, by condensation of a 2-amino-3,4-dihydro-1(2H)-isoquinolinone with an imidolyl, cyanamide, cyanic or thiocyanic derivative. New compounds of the formula I wherein A represents the group --CH2 --CH2 -- or --CH=CH--, R has the same meaning as above with the exclusion of hydrogen, methyl, phenyl, and trifluoromethyl, R1 and R2 have the same meaning as above, with the proviso that when A represents the group --CH=CH--, R cannot be tolyl or pyridyl. The new compounds and some of the intermediates of the process are active as antiinflammatories, CNS depressants and anti-fertility agents.

2-Substituted phenyl-5-triazols [5,1-a] isoquinoline compounds

A new process for preparing s-triazolo[5,1-a]-isoquinoline derivatives of the formula STR1 wherein A represents the group --CH2 --CH2 -- or --CH=CH--; R is selected from hydrogen, amino, lower alkylamino, di-lower alkylamino, acylamino, diacylamino, ureido, thioureido, carbethoxythioureido, benzoylthioureido, sulfhydryl, lower alkyl, trifluoromethyl, phenyl, substituted phenyl, pyridyl, methylpyridyl and dimethylpyridyl; and R1 and R2 each independently represents hydrogen or lower alkoxy; by condensation of a 2-amino-3,4-dihydro-1(2H)-isoquinolinone with an imidolyl, cyanamide, cyanic or thiocyanic derivative. New compounds of the formula I wherein A represents the group --CH2 --CH2 -- or --CH=CH--, R has the same meaning as above with the exclusion of hydrogen, methyl, phenyl, and trifluoromethyl, R1 and R2 have the same meaning as above, with the proviso that when A represents the group --CH=CH--, R cannot be tolyl or pyridyl. The new compounds and some of the intermediates of the process are active as antiinflammatories, CNS depressants and anti-fertility agents.